Trial Parameters
Brief Summary
This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Eligibility Criteria
Inclusion Criteria: * Adult patients (greater than 18 years of age) with a known or suspected intracranial tumor. * Able to provide informed written consent and/or acceptable surrogate capable of providing consent on the patient's behalf. * Legally authorized representative (LAR)-signed informed consent and assent obtained for those subjects identified as decisionally impaired * Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2/fluid attenuated inversion recovery (FLAIR) MR imaging. * Karnofsky performance score \> 60 or Eastern Cooperative Oncology Group (ECOG) \< 3 as assessed by referring clinician. * Planning to undergo or previously received therapeutic intervention for the intracranial tumor. Exclusion Criteria: * Pregnant or breast feeding. * Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents. * Claustrophobia. * Weight greater than modality maximum capacity. * Presence of metallic foreign body or impla